Abstract

Hydrogel compositions prepared from amine components and glycidyl ether components are provided which are biocompatible and suitable for use in vivo due, in part, to their excellent stability.

Drawings

Claims42

Dependent claims

A biocompatible composition comprising a biocompatible solution comprising:

(a) a diamine;
(b) a polyglycidyl ether;
and
(c) a buffer solution comprising glycine-glycine;
wherein said biocompatible solution does not form emboli in the blood;
wherein said biocompatible solution forms a substantially water-insoluble hydrogel within about 20 minutes or less at a biocompatible temperature in the body;
and
wherein the polyglycidyl ether and diamine are present in a ratio such that biocompatibility is preserved.

5 more elements

Dependencies are inferred from the claim text.

Back to results

US 9,308,301 B2Granted

Non-degradable, low swelling, water soluble radiopaque hydrogel polymer

AssigneeTriVascular, Inc.

InventorsSyed H. Askari, Robert G. Whirley

Life of this patent

About 1 year 11 months of term left · ends 30 Sep 2028 (estimated)

Priority1 Apr 2005

Filed19 Apr 2011

Published11 Aug 2011

Granted12 Apr 2016

Today12 Oct 2026

Term ends30 Sep 2028

Priority1 Apr 2005

Granted12 Apr 2016

Term ends30 Sep 2028

Life of this patent

Estimating the term…

Abstract

Hydrogel compositions prepared from amine components and glycidyl ether components are provided which are biocompatible and suitable for use in vivo due, in part, to their excellent stability.

Drawings

Drawings are temporarily unavailable. Open the PDF at USPTO

Drawings

Claims42

Dependent claims

A biocompatible composition comprising a biocompatible solution comprising:

(a) a diamine;
(b) a polyglycidyl ether;
and
(c) a buffer solution comprising glycine-glycine;
wherein said biocompatible solution does not form emboli in the blood;
wherein said biocompatible solution forms a substantially water-insoluble hydrogel within about 20 minutes or less at a biocompatible temperature in the body;
and
wherein the polyglycidyl ether and diamine are present in a ratio such that biocompatibility is preserved.

5 more elements

Dependencies are inferred from the claim text.

Description10,550 words

Summary2,340 words

#Not Applicable

#The present invention relates to the development of hydrogel polymer compositions that are non-degradable, low-swelling and initially water soluble. More specifically, the hydrogel polymer compositions may be formed in situ and are useful as, e.g., embolic materials, bulking agents, and inflation or support media for certain types of medical devices. The present invention additionally includes a kit for preparing the hydrogel polymer compositions.

Detailed description8,210 words

#Not Applicable.

#As used herein, the term “biocompatible” describes the characteristic of a polymer or other material to not have a toxic or injurious effect (i.e., does not cause infection or trigger an immune attack, or adversely affect the biological function in the expected conditions of use) in a mammalian biologic system.

#As used herein, the term “radiopaque” or “contrast agent” is used to describe a material that is not transparent to X-rays or other forms of radiation. Radiopaque materials include but are not limited to sodium iodide, potassium iodide, barium sulfate, gold, tungsten, platinum, metrizamide, iopamidol, iohexol, iothalamate sodium, meglumine, Visipaque 320, Hypaque, Omnipaque 350, Hexabrix and tantalum powder).

Facts

Application: 13/089,960Filed 19 Apr 2011 · continuation
Priority: 1 Apr 2005
Published: US 2011/0196060 A111 Aug 2011
Granted: 12 Apr 2016
Term ends: 30 Sep 2028
Estimated · howhide
20 years from earliest known nonprovisional domestic filing plus recorded patent term adjustment, including 1,278 days of adjustment. Maintenance-fee lapses, terminal disclaimers and statutory extensions have not been checked. The continuity chain may be incomplete; this is not an enforceability determination.

Classification9 codes

A61L 31/06
Macromolecular materials: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61K 49/0457
Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a…:…
A61L 24/0031
Use of materials characterised by their function or physical properties: hydrogels or hydrocolloids
A61L 31/145
Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface…:…

Family

Application11/097,467Parent of this continuation · filed 1 Apr 2005
US 2011/0196060 A1Pre-grant publication · published 11 Aug 2011
US 2006/0222596 A1Published application
US 9,308,301 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

1 Apr 2005Priority claimedParent application 11/097,467
19 Apr 2011Application filedUS 13/089,960
11 Aug 2011PublishedUS 2011/0196060 A1
12 Oct 2012Assigned to Capital Royalty Partners II L.P., Parallel Investment Opportunities Partners II L.P.short-form patent security agreement
4 Feb 2016Assigned to Trivascular, Inc.release of security interest in patent rights
12 Apr 2016GrantedUS 9,308,301 B2
3 Apr 2017Assigned to Deerfield Private Design Fund Iv, L.P., AS Agentsecurity interest
3 Apr 2017Assigned to Deerfield Elgx Revolver, LLC, AS Agentsecurity interest
12 Jan 2018Assigned to Endologix, Inc., Nellix, Inc., Trivascular, Inc.release of security interest
10 Aug 2018Assigned to Deerfield Elgx Revolver, LLC, AS Agentsecurity interest
2 Oct 2020Assigned to Deerfield Private Design Fund Iv, L.P.security interest
2 Oct 2020Assigned to Endologix LLCchange of name
1 Apr 2021Assigned to Silicon Valley Banksecurity interest
12 Oct 2026TodayWithin its term
30 Sep 2028Term endsEstimated, includes 1,278 days of adjustment

Citations

1–5 of 61